Xarelto Makers’ Hopes Squashed A Second Time
Xarelto Makers’ Hopes Squashed A Second Time
Introduction
Portola Pharmaceuticals received news of a second-time delay from the U.S. Food & Drug Administration (FDA) regarding the approval of AndexXa, an antidote developed to monitor uncontrollable bleeding linked to Xarelto and Eliquis. The delay is caused due to some additional data required by the FDA, shifting the expected approval date from February 3, 2018, to May 4, 2018.
Prior to this, the FDA had delayed the August of 2016 approval, when it reverted requesting more information about Portola’s manufacturing and additional data for inclusion of two other anticoagulants in the label: edoxaban and enoxaparin. The makers of anticoagulants Xarelto and Eliquis, Bayer and Johnson & Johnson as well as Pfizer and Bristol-Myers Squibb, have been funding Portola to develop the antidote in view that it will bring the much awaited legal respite be ‘the legal sheath’ to help them evade new lawsuits tied to the bleeding risks of their drugs.
Previously three verdicts have been announced in favor of the defendants by Honorable Eldon E. Fallon presiding MDL – 2592: Xarelto Products Liability Litigation in the U.S. District Court for the Eastern District of Louisiana.
Latest News
Study Links Roundup Chemical to Long-Term Brain Damage
A recent study suggests that exposure to the widely used herbicide Roundup, which contains the active ingredient glyphosate, may be…
Zimmer Biomet Gets FDA Approval for Cementless Partial Knee
Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…
Court Names Special Masters for Bard Mesh Claim Settlements
The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…